ºñÁ¤¸Æ·ù »óºÎÀ§Àå°ü ÃâÇ÷ 2018 ¾Æ½Ã¾Æ-ÅÂÆò¾ç °¡À̵å¶óÀÎ ¼Ò°³
A Review of the 2018 Asia-Pacific Working Group Consensus on Non-variceal Upper Gastrointestinal Bleeding
±èÁؼº, ±èº´¿í,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁؼº ( Kim Joon-Sung )
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÎõ¼º¸ðº´¿ø ¼Òȱ⳻°ú
±èº´¿í ( Kim Byung-Wook )
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ÀÎõ¼º¸ðº´¿ø ¼Òȱ⳻°ú
Abstract
Despite recent advances in endoscopic techniques and acid-suppressive therapies, non-variceal upper gastrointestinal bleeding (NVUGIB) is still associated with significant morbidity and mortality. The increased use of dual antiplatelet agents and oral anticoagulants has complicated the management of NVUGIB. Physicians often have to decide on when to discontinue and resume these medications in patients with NVUGIB. However, clinical data regarding the resumption of antiplatelets and anticoagulants are still minimal. Here, we report and summarize the key recommendations made in the recent Asia-Pacific guidelines regarding management of antithrombotics in patients with NVUGIB.
Å°¿öµå
Non-variceal upper gastrointestinal bleeding; Guideline; Platelet aggregation inhibitors; Anticoagulants
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸